Medocity’s REACH platform transforms and accelerates patient recruitment, eligibility and enrollment for a leading biotech company


Applying digital innovation in a Phase 2 Clinical Program focused on Rare Genetic Diseases

Parsippany, NJ – February 16, 2023

A commercial-stage Biotech company focused on rare genetic diseases has partnered with Medocity, a leading digital health technology company, deploying Medocity’s REACH™ platform to help accelerate recruitment, qualification and management of patient eligibility and enrollment in their clinical trials. The company is conducting a comprehensive, multi-study Phase 2 clinical trial program at more than 75 trial sites across 12 countries with an enrollment goal of 500 pediatric and adult patients.

Within six months of launching Medocity’s Platform, the Biotech company realized the following results:

  • a dramatic increase in identified and qualified patients
  • a multi-fold decrease in enrollment timelines across all trials
  • significant expansion of their HCP referral and patient repository network.

Currently, Medocity is helping to expedite program enrollment at over 45 sites in the U.S. with over 9,500 patients identified and qualified through the Medocity REACH platform to date.

Medocity’s state-of-the-art REACH™ platform has access to over 350 million patient and associated HCP data records from multiple sources including 5 billion annual claims.  The platform provides actionable data to accelerate patient-matching, screening and enrollment timelines, enable real-time referrals to sites and providers, and streamline coordination with site investigators through a digitally-connected trial ecosystem.

Medocity’s highly interoperable platform integrates with genomic labs to capture and stratify hard-to-find patients based on genotype or disease biomarker, connecting with the trial hub, and providing a rapid and efficient flow of external clinical data combined with protocol criteria matching within one seamless, centralized solution.

In addition to accelerating recruitment and enrollment timelines, other key benefits include:

  • Improving access to patients in diverse populations and geographies around the world
  • Delivering immediate actionable real-world data, streamlined workflows, and visibility to cohort status enabling real-time interactions for key stakeholders
  • Enabling enrollment and HCP referrals for the sponsor, HCPs, sites, CRO and field teams via customized portals and dashboards
  • Developing and maintaining patient repositories with genomic and biomarker data for future trials and patient support

“We’re excited to contribute in such a meaningful role to this important, ground-breaking rare disease program and to provide an efficient and cost-effective recruitment and enrollment solution for our customer,” said Amy Apostoleris, Global Head of DCT Solutions at Medocity, “Our collaboration not only puts us at the forefront of digital innovation but also reinforces our commitment to diversity, equity and inclusion, thus making it easier for all patients to enroll in clinical trials in their communities and ultimately improve their lives, which at the end of the day, is the most gratifying contribution of all.”

About Medocity

Medocity is a leading healthcare technology company serving the pharmaceutical industry from clinical development through commercialization to transform patient data collection and management of chronic and co-morbid conditions. The company’s next generation technology platform and AI/ML-driven algorithms enable its clients to rapidly deploy comprehensive patient-centered ecosystems, digital patient support programs, and decentralized/hybrid/virtual clinical trials globally through a single enterprise solution. Clinically proven across multiple chronic conditions and settings, the Medocity Platform increases engagement, retention, and compliance, accelerates study timelines, improves outcomes, and lowers total healthcare costs. Any disease. Any drug. Any device. Anywhere.

For more information, please visit www.medocity.com

#     #     #